Arginase activity - a marker of disease status in patients with visceral leishmaniasis in ethiopia.

Détails

Ressource 1Télécharger: BIB_EFA9E03DEF24.P001.pdf (743.72 [Ko])
Etat: Public
Version: de l'auteur
ID Serval
serval:BIB_EFA9E03DEF24
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Titre
Arginase activity - a marker of disease status in patients with visceral leishmaniasis in ethiopia.
Périodique
PLoS Neglected Tropical Diseases
Auteur(s)
Abebe T., Takele Y., Weldegebreal T., Cloke T., Closs E., Corset C., Hailu A., Hailu W., Sisay Y., Corware K., Corset M., Modolell M., Munder M., Tacchini-Cottier F., Müller I., Kropf P.
ISSN
1935-2735 (Electronic)
ISSN-L
1935-2727
Statut éditorial
Publié
Date de publication
2013
Volume
7
Numéro
3
Pages
e2134
Langue
anglais
Résumé
The underlying mechanisms resulting in the profound immune suppression characteristic of human visceral leishmaniasis (VL) are not fully understood. Here, we tested the hypothesis that arginase, an enzyme associated with immunosuppression, is higher in patients with VL and contributes to impaired T cell responses. We recruited patients with VL before and after treatment and healthy controls and measured the arginase metabolism in the blood of these individuals. Our results show that arginase activity is significantly higher in the blood of patients with active VL as compared to controls. These high levels of arginase decline considerably once the patients are successfully treated. We identified the phenotype of arginase-expressing cells among PBMCs as neutrophils and show that their frequency was increased in PBMCs of patients before treatment; this coincides with reduced levels of L-arginine in the plasma and decreased expression levels of CD3ζ in T cells.
Pubmed
Web of science
Open Access
Oui
Création de la notice
03/05/2013 8:38
Dernière modification de la notice
20/08/2019 17:17
Données d'usage